Abstract: The present invention concerns substituted indole derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Inventors:
Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
Abstract: The present invention relates to substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Inventors:
Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Erwin Coesemans, Pierre Jean-Marie Bernard Raboisson, Arnaud Didier M Marchand, Dorothée Alice Marie-Eve Bardiot
Abstract: An injection device and an injection device trainer for training a user to use an injection device. Each one of the injection device and the injection device trainer can include: a body portion; and an actuator positioned towards a proximal end of the body portion, the actuator moveable from a proximal position to a distal position; wherein the body portion comprises a body protrusion and the actuator comprises a latch that is arranged to couple with the body protrusion when the actuator is in the distal position, thus holding the actuator in the distal position.
Abstract: An injection device and an injection device trainer for training a user to use an injection device. Each one of the injection device and the injection device trainer can include: a body portion; an actuator positioned towards a proximal end of the body portion, the actuator moveable from a proximal position to a distal position; a shield positioned towards a distal end of the body portion, the shield moveable between: an initial position; an extended position that is more distal relative to the body portion than the initial position; and a connector that connects the actuator to the shield such that movement of the actuator from the distal position towards the proximal position pulls the shield from the extended position to the initial position.
Abstract: An injection device and an injection device trainer for training a user to use an injection device. Each one of the injection device and the injection device trainer can include: a body portion; an actuator positioned towards a proximal end of the body portion, the actuator moveable from a proximal position to a distal position; a shield positioned towards a distal end of the body portion, the shield moveable between: an initial position; a retracted position that is more proximal relative to the body portion than the initial position; and an extended position that is more distal relative to the body portion than the initial position; and a locking member rotatable between a first orientation in which the locking member resists movement of the actuator from the proximal position to the distal position; and a second orientation in which the locking member permits the actuator to move from the proximal position to the distal position.
Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
Type:
Grant
Filed:
August 24, 2016
Date of Patent:
March 10, 2020
Assignees:
GlaxoSmithKline Biological S.A., Janssen Pharmaceuticals, Inc.
Inventors:
Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Inventors:
Dorothée Alice Marie-Eve Bardiot, Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Pierre Jean-Marie Bernard Raboisson, Arnaud Didier M. Marchand
Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.
Type:
Grant
Filed:
April 12, 2017
Date of Patent:
January 21, 2020
Assignee:
Janssen Pharmaceuticals, Inc.
Inventors:
Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
Abstract: Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing E. coli antigen polysaccharide covalently bound to a exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
January 7, 2020
Assignee:
Janssen Pharmaceuticals, Inc.
Inventors:
Olga Labovitiadi, Wouter Frank Tonnis, Francesco Doro, Janik Adriaansen
Abstract: The present invention concerns substituted indole derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
August 6, 2019
Assignee:
JANSSEN PHARMACEUTICALS, INC.
Inventors:
James Andrew Huntington, Trevor Baglin, Jonathan Langdown
Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
June 18, 2019
Assignee:
JANSSEN PHARMACEUTICALS, INC.
Inventors:
Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
May 14, 2019
Assignee:
Janssen Pharmaceuticals, Inc.
Inventors:
James Andrew Huntington, Trevor Baglin, Jonathan Langdown
Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
Type:
Grant
Filed:
September 11, 2017
Date of Patent:
April 30, 2019
Assignees:
Biocerox Products B.V., Janssen Pharmaceuticals, Inc.
Inventors:
Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
Abstract: The present invention concerns mono- or di-substituted indole compounds of formula (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Inventors:
Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
Abstract: Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing E. coli antigen polysaccharide covalently bound to a exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.
Type:
Grant
Filed:
October 24, 2017
Date of Patent:
December 25, 2018
Assignee:
JANSSEN PHARMACEUTICALS, INC.
Inventors:
Olga Labovitiadi, Wouter Frank Tonnis, Francesco Doro, Janik Adriaansen
Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
Type:
Grant
Filed:
August 14, 2015
Date of Patent:
December 18, 2018
Assignee:
JANSSEN PHARMACEUTICALS, INC.
Inventors:
Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward
Abstract: The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of the 3-month formulation of paliperidone palmitate.
Type:
Grant
Filed:
April 5, 2016
Date of Patent:
December 4, 2018
Assignee:
Janssen Pharmaceuticals, Inc.
Inventors:
Srihari Gopal, Paulien Gerarda Maria Ravenstijn, Alberto Russu, Mahesh Narain Samtani
Abstract: The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Inventors:
Bart Rudolf, Romanie KESTELEYN, Jean-François BONFANTI, Tim Hugo, Maria JONCKERS, Pierre Jean-Marie, Bernard RABOISSON, Dorothée Alice, Marie-Eve BARDIOT, Arnaud Didier, M MARCHAND
Abstract: The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Inventors:
Bart Rudolf, Romanie KESTELEYN, Jean-François BONFANTI, Tim Hugo, Maria JONCKERS, Pierre Jean-Marie, Bernard RABOISSON, Dorothée Alice, Marie-Eve BARDIOT, Arnaud Didier, M MARCHAND